Department of Pharmaceutical Chemistry, College of Pharmacy, University of Hail, Hail, Kingdom Saudi Arabia.
Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.
Curr Neuropharmacol. 2023;21(4):988-1000. doi: 10.2174/1570159X20666220327212414.
Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders, affecting the basal nuclei, causing impairment of motor and cognitive functions. Loss of dopaminergic (DAergic) neurons or their degeneration and the aggregation of Lewy bodies is the hallmark of this disease. The medications used to treat PD relieve the symptoms and maintain quality of life, but currently, there is no cure. There is a need for the development of therapies that can cease or perhaps reverse neurodegeneration effectively. With the rapid advancements in cell replacement therapy techniques, medical professionals are trying to find a cure by which restoration of dopamine neurotransmitters can occur. Researchers have started focusing on cell-based therapies using mesenchymal stem cells (MSCs) due to their abundance in the body, the ability of proliferation, and immunomodulation. Here we review the MSC-based treatment in Parkinson's disease and the various mechanisms it repairs DAergic neurons in parkinsonian patients.
帕金森病(PD)是最常见的神经退行性疾病之一,影响基底核,导致运动和认知功能受损。多巴胺能(DAergic)神经元的丧失或其退化以及路易体的聚集是这种疾病的标志。用于治疗 PD 的药物可缓解症状并维持生活质量,但目前尚无治愈方法。需要开发能够有效停止或可能逆转神经退行性变的治疗方法。随着细胞替代治疗技术的快速发展,医务人员正试图通过恢复多巴胺神经递质来寻找治疗方法。由于体内大量存在、增殖能力和免疫调节能力,研究人员已开始专注于使用间充质干细胞(MSCs)的基于细胞的疗法。在这里,我们回顾了基于 MSC 的帕金森病治疗方法,以及它修复帕金森病患者 DAergic 神经元的各种机制。